Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

KRISTOPHER S LYBARGER

Allopathic & Osteopathic Physicians Obstetrics & Gynecology Gynecologic Oncology

NPI
1013172022
CMS profile
477864
Location
KANSAS CITY, MO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$208,909.64

200 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Page 4 of 4; records 151–200 of 200 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

KRISTOPHER S LYBARGER

NPI 1013172022 · CMS profile ID 477864

Allopathic & Osteopathic Physicians / Obstetrics & Gynecology / Gynecologic Oncology

KANSAS CITY, MO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 4; records 151–200 of 200 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1013172022?year=2023&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
KRISTOPHER S LYBARGER, NPI 1013172022, CMS profile ID 477864. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–200 of 200 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1013172022?year=2023&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). KRISTOPHER S LYBARGER, NPI 1013172022, CMS profile ID 477864. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–200 of 200 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1013172022?year=2023&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
KRISTOPHER S LYBARGER, NPI 1013172022, CMS profile ID 477864, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 4; records 151–200 of 200 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1013172022?year=2023&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

200 matching records · $208,909.64 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 200 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–200 of 200.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Seagen Inc. $265.6405/18/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 995661287 CMS
Janssen Biotech, Inc. $99.0005/17/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988231623 CMS
Davol Inc. $173.6905/15/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023917195 CMS
Davol Inc. $642.3005/15/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023917197 CMS
Davol Inc. $4,200.0005/12/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023917057 CMS
Myriad Genetic Laboratories, Inc. $2,100.0005/11/2023 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059785157 CMS
Davol Inc. $96.8105/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023917189 CMS
Davol Inc. $157.9005/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023917191 CMS
GlaxoSmithKline, LLC. $1,600.0005/10/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003467275 CMS
Davol Inc. $1,500.0005/09/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023917055 CMS
Davol Inc. $1,573.6605/09/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023917187 CMS
Davol Inc. $319.3805/08/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023917157 CMS
Davol Inc. $342.8005/08/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023917159 CMS
Davol Inc. $22.3205/08/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023917161 CMS
Myriad Genetic Laboratories, Inc. $55.2205/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059785153 CMS
Davol Inc. $375.0005/02/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023917053 CMS
Davol Inc. $592.9905/01/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023917183 CMS
Davol Inc. $231.7504/24/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023917185 CMS
Merck Sharp & Dohme LLC $27.4204/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048541289 CMS
Davol Inc. $4,000.0004/19/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023917059 CMS
Davol Inc. $4,000.0004/19/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023917073 CMS
Ethicon US, LLC $28.2804/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 990847421 CMS
Davol Inc. $980.6104/07/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023917181 CMS
Davol Inc. $128.2504/03/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023917179 CMS
Genmab U.S., Inc. $36.9303/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051345949 CMS
Davol Inc. $144.5203/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023917077 CMS
Davol Inc. $117.6403/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023917075 CMS
Davol Inc. $1,500.0003/08/2023 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023917037 CMS
Davol Inc. $1,500.0003/08/2023 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023917049 CMS
Davol Inc. $4,200.0003/06/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023917039 CMS
Genmab U.S., Inc. $16.3803/06/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051345957 CMS
Genmab U.S., Inc. $119.5703/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051345955 CMS
Davol Inc. $45.0103/03/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023917177 CMS
Genmab U.S., Inc. $2,375.0003/02/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051345961 CMS
Davol Inc. $739.4002/24/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023917175 CMS
Davol Inc. $3,000.0002/23/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023917041 CMS
Davol Inc. $2,456.3702/15/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023917173 CMS
Davol Inc. $4,200.0002/14/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023917043 CMS
Davol Inc. $358.1802/14/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023917151 CMS
Davol Inc. $187.7802/14/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023917165 CMS
Davol Inc. $156.4702/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023917047 CMS
Davol Inc. $147.6102/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023917033 CMS
Davol Inc. $146.0502/02/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023917147 CMS
Davol Inc. $161.0502/02/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023917149 CMS
GlaxoSmithKline, LLC. $4,800.0002/01/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003467279 CMS
GlaxoSmithKline, LLC. $1,200.0001/18/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003467015 CMS
Merck Sharp & Dohme LLC $22.1501/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048814441 CMS
Davol Inc. $365.9401/11/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023917145 CMS
GlaxoSmithKline, LLC. $4,800.0001/11/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003467545 CMS
Takeda Pharmaceuticals U.S.A., Inc. $20.1601/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055464651 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $132,254.95 202
PY2020 $12,935.72 40
PY2021 $25,527.82 46
PY2022 $96,049.00 123
PY2023 $208,909.64 200
PY2024 $187,523.66 203
PY2025 $79,755.94 121

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $100,294.28 42
PY2024 Principal investigator $83,472.67 19
PY2023 Principal investigator $61,913.40 24
PY2022 Principal investigator $229,853.97 61
PY2021 Principal investigator $104,074.52 50
PY2020 Principal investigator $127,667.83 29
PY2019 Principal investigator $347,388.26 35

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

42 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Genmab U.S., Inc. $28,550.00 11/20/2025 Non-covered Recipient Entity
HCA RESEARCH INSTITUTE, LLC
A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator's Choice (IC) in Patients With Platinum Resistant Ovarian Cancer No dispute reported 06/30/2026 1235930607
Principal investigator 1 Karyopharm Therapeutics Inc. $1,363.32 08/27/2025 Covered Recipient Teaching Hospital
White Plains Hospital
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246662263
Principal investigator 1 Karyopharm Therapeutics Inc. $1,363.32 08/27/2025 Covered Recipient Teaching Hospital
White Plains Hospital
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246662271
Principal investigator 1 Karyopharm Therapeutics Inc. $1,363.32 08/27/2025 Covered Recipient Teaching Hospital
White Plains Hospital
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246662301
Principal investigator 1 Karyopharm Therapeutics Inc. $1,645.32 08/27/2025 Covered Recipient Teaching Hospital
White Plains Hospital
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246662305
Principal investigator 1 Karyopharm Therapeutics Inc. $1,363.32 08/27/2025 Covered Recipient Teaching Hospital
White Plains Hospital
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246662319
Principal investigator 1 Karyopharm Therapeutics Inc. $1,363.32 08/27/2025 Covered Recipient Teaching Hospital
White Plains Hospital
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246662325
Principal investigator 1 Karyopharm Therapeutics Inc. $2,056.32 08/27/2025 Covered Recipient Teaching Hospital
White Plains Hospital
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246662327
Principal investigator 1 Karyopharm Therapeutics Inc. $1,363.32 08/27/2025 Covered Recipient Teaching Hospital
White Plains Hospital
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246662329
Principal investigator 1 Karyopharm Therapeutics Inc. $4,324.32 07/29/2025 Covered Recipient Teaching Hospital
White Plains Hospital
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246662265
Principal investigator 1 Karyopharm Therapeutics Inc. $183.00 06/04/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
A Randomized, Double-Blind, Phase 3 Trial of Maintenance with Selinexor/Placebo After Combination Chemotherapy for Patients with Advanced or Recurrent Endometrial Cancer No dispute reported 06/30/2026 1246664468
Principal investigator 1 Karyopharm Therapeutics Inc. $1,469.70 06/04/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
A Randomized, Double-Blind, Phase 3 Trial of Maintenance with Selinexor/Placebo After Combination Chemotherapy for Patients with Advanced or Recurrent Endometrial Cancer No dispute reported 06/30/2026 1246664484
Principal investigator 1 Karyopharm Therapeutics Inc. $1,363.32 05/15/2025 Covered Recipient Teaching Hospital
White Plains Hospital
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246662261
Principal investigator 1 Karyopharm Therapeutics Inc. $1,363.32 05/15/2025 Covered Recipient Teaching Hospital
White Plains Hospital
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246662291
Principal investigator 1 Karyopharm Therapeutics Inc. $1,363.32 05/15/2025 Covered Recipient Teaching Hospital
White Plains Hospital
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246662293
Principal investigator 1 Karyopharm Therapeutics Inc. $1,363.32 05/15/2025 Covered Recipient Teaching Hospital
White Plains Hospital
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246662313
Principal investigator 1 Karyopharm Therapeutics Inc. $1,363.32 05/15/2025 Covered Recipient Teaching Hospital
White Plains Hospital
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246662333
Principal investigator 1 Karyopharm Therapeutics Inc. $1,363.32 05/15/2025 Covered Recipient Teaching Hospital
White Plains Hospital
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246662335
Principal investigator 1 Karyopharm Therapeutics Inc. $1,186.20 02/10/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
A Randomized, Double-Blind, Phase 3 Trial of Maintenance with Selinexor/Placebo After Combination Chemotherapy for Patients with Advanced or Recurrent Endometrial Cancer No dispute reported 06/30/2026 1246664458
Principal investigator 1 Karyopharm Therapeutics Inc. $16,712.64 01/27/2025 Covered Recipient Teaching Hospital
White Plains Hospital
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246662281
Principal investigator 1 Karyopharm Therapeutics Inc. $1,363.32 01/23/2025 Covered Recipient Teaching Hospital
White Plains Hospital
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246662267
Principal investigator 1 Karyopharm Therapeutics Inc. $2,056.32 01/23/2025 Covered Recipient Teaching Hospital
White Plains Hospital
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246662269
Principal investigator 1 Karyopharm Therapeutics Inc. $1,363.32 01/23/2025 Covered Recipient Teaching Hospital
White Plains Hospital
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246662273
Principal investigator 1 Karyopharm Therapeutics Inc. $1,449.00 01/23/2025 Covered Recipient Teaching Hospital
White Plains Hospital
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246662275
Principal investigator 1 Karyopharm Therapeutics Inc. $1,277.64 01/23/2025 Covered Recipient Teaching Hospital
White Plains Hospital
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246662277
Principal investigator 1 Karyopharm Therapeutics Inc. $1,363.32 01/23/2025 Covered Recipient Teaching Hospital
White Plains Hospital
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246662279
Principal investigator 1 Karyopharm Therapeutics Inc. $246.96 01/23/2025 Covered Recipient Teaching Hospital
White Plains Hospital
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246662283
Principal investigator 1 Karyopharm Therapeutics Inc. $1,363.32 01/23/2025 Covered Recipient Teaching Hospital
White Plains Hospital
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246662285
Principal investigator 1 Karyopharm Therapeutics Inc. $1,155.42 01/23/2025 Covered Recipient Teaching Hospital
White Plains Hospital
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246662287
Principal investigator 1 Karyopharm Therapeutics Inc. $1,277.64 01/23/2025 Covered Recipient Teaching Hospital
White Plains Hospital
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246662289
Principal investigator 1 Karyopharm Therapeutics Inc. $1,363.32 01/23/2025 Covered Recipient Teaching Hospital
White Plains Hospital
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246662295
Principal investigator 1 Karyopharm Therapeutics Inc. $1,277.64 01/23/2025 Covered Recipient Teaching Hospital
White Plains Hospital
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246662297
Principal investigator 1 Karyopharm Therapeutics Inc. $1,181.88 01/23/2025 Covered Recipient Teaching Hospital
White Plains Hospital
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246662299
Principal investigator 1 Karyopharm Therapeutics Inc. $1,363.32 01/23/2025 Covered Recipient Teaching Hospital
White Plains Hospital
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246662303
Principal investigator 1 Karyopharm Therapeutics Inc. $1,363.32 01/23/2025 Covered Recipient Teaching Hospital
White Plains Hospital
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246662307
Principal investigator 1 Karyopharm Therapeutics Inc. $1,363.32 01/23/2025 Covered Recipient Teaching Hospital
White Plains Hospital
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246662309
Principal investigator 1 Karyopharm Therapeutics Inc. $1,363.32 01/23/2025 Covered Recipient Teaching Hospital
White Plains Hospital
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246662311
Principal investigator 1 Karyopharm Therapeutics Inc. $1,363.32 01/23/2025 Covered Recipient Teaching Hospital
White Plains Hospital
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246662315
Principal investigator 1 Karyopharm Therapeutics Inc. $1,363.32 01/23/2025 Covered Recipient Teaching Hospital
White Plains Hospital
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246662317
Principal investigator 1 Karyopharm Therapeutics Inc. $1,277.64 01/23/2025 Covered Recipient Teaching Hospital
White Plains Hospital
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246662321
Principal investigator 1 Karyopharm Therapeutics Inc. $1,363.32 01/23/2025 Covered Recipient Teaching Hospital
White Plains Hospital
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246662323
Principal investigator 1 Karyopharm Therapeutics Inc. $246.96 01/23/2025 Covered Recipient Teaching Hospital
White Plains Hospital
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246662331